ZIF Nanoparticles With Targeting Ligands for Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer, such as systemic chemotherapy, result in severe side effects due to low specificity, affecting essential organs and causing neurotoxicity and infertility.
Innovation Solution
Nanoparticles containing a zeolitic imidazolate framework (ZIF) cage, a surface modifying agent, a targeting ligand, and an active agent are developed to target and treat prostate cancer cells while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic chemotherapy is used to treat prostate cancer, then cancer cells are killed, but severe side effects occur due to low specificity
Solution Approach 1:
The patent applies local quality by functionalizing the nanoparticle surface with specific ligands (e.g., PSMA-targeting ligands) that provide cancer-selective recognition. This enables the therapeutic agent to exert its killing effect specifically at the cancer cell location while leaving healthy tissues unaffected, thereby resolving the contradiction between effective cancer cell elimination and reduction of off-target side effects
Solution Approach 2:
The nanoparticle serves as an intermediary carrier that transports the cytotoxic agent from the bloodstream to the cancer cell. The surface-modified nanoparticle mediates selective delivery through receptor-mediated endocytosis, allowing the toxic agent to reach only the intended target (cancer cells) without directly exposing healthy organs to the toxic substance, thus resolving the harmful side effect issue
2Reliability
If traditional chemotherapy drugs are administered, then tumor growth is inhibited, but neurotoxicity and infertility occur
Solution Approach 1:
The patent segments the therapeutic system into distinct functional components: a biocompatible nanoparticle carrier and a cytotoxic payload. The carrier is designed with specific surface properties for cancer cell targeting, while the payload provides the tumor growth inhibition function. This segmentation allows the toxic function to be spatially and functionally separated from the delivery system, preventing systemic toxicity while maintaining therapeutic efficacy
Solution Approach 2:
The patent changes the physical and chemical parameters of the drug delivery system by using nanoparticles with controlled size (20-200 nm), surface charge, and composition. These parameter changes enable enhanced permeability and retention (EPR) effect for passive tumor targeting, along with active targeting through surface ligands, thereby achieving tumor-specific delivery that avoids neurotoxicity and infertility associated with conventional chemotherapy
3Reliability
If high doses of chemotherapy are used to improve treatment effectiveness, then cancer cells are more effectively killed, but side effects on essential organs increase
Solution Approach 1:
The patent applies preliminary action by pre-functionalizing the nanoparticle surface with targeting ligands before drug loading. This preliminary surface modification ensures that the nanoparticle is pre-configured for selective cancer cell recognition and uptake, enabling high-dose drug delivery to be concentrated at the tumor site from the outset, thereby maximizing cancer cell killing while minimizing exposure of healthy organs to toxic agents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles effectively target and kill prostate cancer cells, reducing symptoms and minimizing side effects compared to traditional chemotherapy methods.
Implementation Method 1
The cage is a 3-dimensional structure that contains an opening for encapsulating a substance therein
Implementation Method 2
a surface modifying agent
Implementation Method 3
a targeting ligand
Data Source
AI summary
Nanoparticles and formulations for treating prostate cancer in a subject are disclosed. The nanoparticles contain a cage, such as a zeolitic imidazolate framework (“ZIF”), a surface modifying agent, a targeting ligand, and an active agent. The surface modifying ligand is attached to the outer surface of the cage and the targeting ligand is exposed to the surrounding environment. The active agent is encapsulated in the cage. The targeting ligand binds to a reproductive hormone or a receptor of a reproductive hormone. The active agents can be a ribosome inactivating protein, an apoptosis inducer, a hormone, a receptor ligand, or a nucleic acid, or a chemotherapy drug or a combination thereof, that kill and/or reduce or prevent growth or proliferation of gonadotroph cells and/or tumor cells, regulate FSH and/or LH secretion, and/or interfere with androgen production. Uses for formulations incorporating the nanoparticles for treating cancer in a subject are also disclosed.